Gilead Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,798 Mil. Gilead Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $23,189 Mil. Gilead Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $22,833 Mil.
Gilead Sciences's debt to equity for the quarter that ended in Dec. 2023 was 1.09.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Gilead Sciences's Debt-to-Equity or its related term are showing as below:
GILD'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.8 Med: 1.23 Max: 1.73
Current: 1.09
During the past 13 years, the highest Debt-to-Equity Ratio of Gilead Sciences was 1.73. The lowest was 0.80. And the median was 1.23.
Gilead Sciences Debt-to-Equity Historical Data
The historical data trend for Gilead Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Gilead Sciences Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
1.09 |
1.73 |
1.27 |
1.19 |
1.09 |
|
Gilead Sciences Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.19 |
1.20 |
1.19 |
1.12 |
1.09 |
Competitive Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Debt-to-Equity Distribution
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Debt-to-Equity falls into.
Gilead Sciences Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Gilead Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Gilead Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (Gilead Sciences) Business Description
Traded in Other Exchanges
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Executives
| Andrew D Dickinson |
officer: EVP, Chief Financial Officer |
333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Johanna Mercier |
officer: Chief Commercial Officer |
333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Merdad Parsey |
officer: Chief Medical Officer |
333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Sandra Patterson |
officer: SVP, Controllership |
333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Diane E. Wilfong |
officer: SVP, Controller & CAO |
333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Deborah H Telman |
officer: EVP, Corporate Affairs & GC |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Brett A Pletcher |
officer: EVP, Gen Counsel & Corp Sec |
333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
| Jeffrey Bluestone |
director |
C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858 |
| Anthony Welters |
director |
|
| Javier Rodriguez |
director |
601 HAWAII ST., EL SEGUNDO CA 90245 |
| John Francis Cogan |
director |
2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131 |
| Gayle E Wilson |
director |
C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Olsen Per Wold |
director |
C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Sandra Horning |
director |
333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
| Richard James Whitley |
director |
UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711 |
Gilead Sciences (Gilead Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your